Last reviewed · How we verify

NCT04566445

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Terminated Phase 2 Results posted Last updated 28 January 2026
What this trial tests

Phase 2 trial testing GT005 in Dry Age-related Macular Degeneration in 255 participants. Terminated before completion.

Timeline
28 September 2020
Primary endpoint
10 June 2024
10 June 2024

Quick facts

Lead sponsorGyroscope Therapeutics Limited
PhasePhase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment255
Start date28 September 2020
Primary completion10 June 2024
Estimated completion10 June 2024
Sites62 locations across France, United Kingdom, Germany, Poland, Australia, United States, Spain

Drugs / interventions tested

Conditions studied

Sponsor

Gyroscope Therapeutics Limited — full company profile →

Who can join

55 and older, any sex, with Dry Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

The Change From Baseline to Week 72 in Geographic Atrophy (GA) Primary · Baseline, Weeks 12, 24, 36, 48 and 72

GA area as measured by fundus autofluorescence (FAF)

Week 12 (n=75,71,72)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]0.730± 0.0625
GT005 High Dose [2E11 vg]0.752± 0.0634
Untreated Control0.667± 0.0647
Week 24 (n=72,75,71)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]1.151± 0.0833
GT005 High Dose [2E11 vg]1.260± 0.0831
Untreated Control1.054± 0.0860
Week 36 (n=66,66,71)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]1.728± 0.1488
GT005 High Dose [2E11 vg]1.955± 0.1503
Untreated Control1.531± 0.1528
Week 48 (n=64,68,65)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]2.098± 0.1841
GT005 High Dose [2E11 vg]2.535± 0.1853
Untreated Control2.047± 0.1896
Week 72 (n=56,51,54)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]3.225± 0.2337
GT005 High Dose [2E11 vg]3.421± 0.2369
Untreated Control2.919± 0.2412
The Change From Baseline at Week 96 in Geographic Atrophy (GA) Secondary · Baseline, Week 96

GA area as measured by fundus autofluorescence (FAF)

GroupValue95% CI
GT005 Medium Dose [5E10 vg]4.414± 0.3109
GT005 High Dose [2E11 vg]4.607± 0.3167
Untreated Control3.769± 0.3286
Summary of Adverse Events Secondary · Adverse events are reported from randomization to the end of study, at Week 96, up to a maximum timeframe of approximately 96 weeks.

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.

Subjects with at least one ocular adverse event for the study eye
GroupValue95% CI
GT005 Medium Dose [5E10 vg]66
GT005 High Dose [2E11 vg]65
Untreated Control15
Subjects with at least one ocular adverse event for the fellow eye
GroupValue95% CI
GT005 Medium Dose [5E10 vg]32
GT005 High Dose [2E11 vg]35
Untreated Control14
Subjects with at least one non-ocular adverse event
GroupValue95% CI
GT005 Medium Dose [5E10 vg]63
GT005 High Dose [2E11 vg]59
Untreated Control44
Subjects with at least one ocular adverse event related to study treatment for the study eye
GroupValue95% CI
GT005 Medium Dose [5E10 vg]13
GT005 High Dose [2E11 vg]21
Untreated Control0
Subjects with at least one non-ocular adverse event related to study treatment
GroupValue95% CI
GT005 Medium Dose [5E10 vg]0
GT005 High Dose [2E11 vg]0
Untreated Control0
Subjects with at least one ocular adverse event related to surgical procedure for the study eye
GroupValue95% CI
GT005 Medium Dose [5E10 vg]48
GT005 High Dose [2E11 vg]48
Untreated Control0
Subjects with at least one non-ocular adverse event related to surgical procedure
GroupValue95% CI
GT005 Medium Dose [5E10 vg]0
GT005 High Dose [2E11 vg]0
Untreated Control0
Subjects with at least one ocular adverse event related to study procedure for the study eye
GroupValue95% CI
GT005 Medium Dose [5E10 vg]8
GT005 High Dose [2E11 vg]9
Untreated Control0
Ocular AEs Occurring in ≥2% of Subjects by Primary System Organ Class and Preferred Term for the Study Eye Secondary · Adverse events are reported from randomization to the end of study, at Week 96, up to a maximum timeframe of approximately 96 weeks.

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

Subjects with at least one event
GroupValue95% CI
GT005 Medium Dose [5E10 vg]66
GT005 High Dose [2E11 vg]65
Untreated Control15
Eye disorders
GroupValue95% CI
GT005 Medium Dose [5E10 vg]65
GT005 High Dose [2E11 vg]62
Untreated Control14
-Cataract
GroupValue95% CI
GT005 Medium Dose [5E10 vg]21
GT005 High Dose [2E11 vg]20
Untreated Control3
-Retinal pigmentation
GroupValue95% CI
GT005 Medium Dose [5E10 vg]12
GT005 High Dose [2E11 vg]22
Untreated Control0
-Conjunctival haemorrhage
GroupValue95% CI
GT005 Medium Dose [5E10 vg]18
GT005 High Dose [2E11 vg]12
Untreated Control1
-Retinal haemorrhage
GroupValue95% CI
GT005 Medium Dose [5E10 vg]8
GT005 High Dose [2E11 vg]10
Untreated Control2
-Eye pain
GroupValue95% CI
GT005 Medium Dose [5E10 vg]5
GT005 High Dose [2E11 vg]7
Untreated Control0
-Ocular hypertension
GroupValue95% CI
GT005 Medium Dose [5E10 vg]6
GT005 High Dose [2E11 vg]6
Untreated Control0
Non-ocular AEs Occurring in ≥2% of Subjects Secondary · Adverse events are reported from randomization to the end of study, at Week 96, up to a maximum timeframe of approximately 96 weeks.

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.

GroupValue95% CI
GT005 Medium Dose [5E10 vg]63
GT005 High Dose [2E11 vg]59
Untreated Control44
Change in GA Morphology From Baseline to Week 96 on Multimodal Imaging - Number of Participants With Increase in Fundus Autofluorescence Secondary · Baseline, Weeks 5, 12, 24, 36, 48, 72 and 96

Change in retinal morphology on multimodal imaging. For the untreated control group, there were no protocol-specified visits at Week 5.

Week 5 (n=23,24,0)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]23
GT005 High Dose [2E11 vg]23
Week 12 (n=75,73,74)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]74
GT005 High Dose [2E11 vg]73
Untreated Control73
Week 24 (n=75,78,72)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]72
GT005 High Dose [2E11 vg]78
Untreated Control71
Week 36 (n=70,70, 71)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]66
GT005 High Dose [2E11 vg]69
Untreated Control70
Week 48 (n=67,72,68)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]67
GT005 High Dose [2E11 vg]71
Untreated Control68
Week 72 (n=61, 62,59)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]60
GT005 High Dose [2E11 vg]60
Untreated Control56
Week 96 (n=52,49, 34)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]50
GT005 High Dose [2E11 vg]48
Untreated Control33
Change in Best Corrected Visual Acuity (BCVA) Score From Baseline Through Week 96 Via the Early Treatment for Diabetic Retinopathy (ETDRS) Chart Secondary · Baseline, Weeks 1, 5, 8, 12, 24, 36, 48, 72 and 96

BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning. For the untreated control group, there were no protocol-specified visits for Weeks 1, 5 and 8.

Week 1 (n=81,78,0)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-2.0± 1.54
GT005 High Dose [2E11 vg]-7.0± 1.56
Week 5 (n=81,78,0)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-0.8± 0.88
GT005 High Dose [2E11 vg]-3.3± 0.89
Week 8 (n=79,77,0)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-0.1± 0.85
GT005 High Dose [2E11 vg]-1.7± 0.86
Week 12 (n=79,79,73)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-1.1± 0.91
GT005 High Dose [2E11 vg]-2.5± 0.91
Untreated Control-0.7± 0.96
Week 24 (n=78,78,71)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-2.7± 1.03
GT005 High Dose [2E11 vg]-6.3± 1.03
Untreated Control-1.1± 1.09
Week 36 (75,74,72)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-2.5± 1.24
GT005 High Dose [2E11 vg]-7.7± 1.25
Untreated Control-3.0± 1.30
Week 48 (n=73,75,69)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-2.6± 1.48
GT005 High Dose [2E11 vg]-7.3± 1.46
Untreated Control-5.3± 1.54
Week 72 (n=63, 70, 58)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-4.1± 1.54
GT005 High Dose [2E11 vg]-7.9± 1.50
Untreated Control-8.8± 1.61
Change in Low Luminance Difference (LLD) Letter Count From Baseline at Weeks 12, 24, 36, 48, 72 and 96, Via Early Treatment for Diabetic Retinopathy (ETDRS) Chart Secondary · Baseline, Weeks 12, 24, 36, 48, 72 and 96

LLD was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. The test was to be performed after BCVA testing, prior to pupil dilation, and distance refraction was to be carried out before Low Luminance Visual Acuity (LLVA) was measured. LLVA was to be measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. The LLD was calculated as the difference between BCVA and LLVA. Initially, letters were to be read at a distance of 4 metres from the chart. If \<20 le

Week 12
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-0.6± 7.59
GT005 High Dose [2E11 vg]-1.1± 9.63
Untreated Control1.2± 9.51
Week 24 (n=78,75,71)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-0.6± 10.10
GT005 High Dose [2E11 vg]-2.5± 12.73
Untreated Control0.5± 12.01
Week 36 (n=75,72,71)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]0.0± 9.90
GT005 High Dose [2E11 vg]-2.6± 13.40
Untreated Control-0.1± 11.12
Week 48 (n=73,73,69)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-0.5± 10.31
GT005 High Dose [2E11 vg]-1.5± 15.18
Untreated Control-0.4± 12.93
Week 72 (n=63,67,58)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-0.5± 13.15
GT005 High Dose [2E11 vg]-5.2± 17.24
Untreated Control-2.5± 14.93
Week 96 (n=54,49,35)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-3.1± 16.11
GT005 High Dose [2E11 vg]-2.2± 13.48
Untreated Control-5.9± 16.82
Reading Performance, Measured as the MRS (Words Per Minute), as Assessed by Minnesota Low-vision Reading Test (MNRead) Chart: Summary Statistics for Change From Baseline by Visit for the Study Eye Secondary · Baseline, Weeks 12, 24, 36, 48, 72 and 96

The maximum reading speed (MRS) represents the highest reading speed an individual can achieve when print size is not a limiting factor. Essentially, it measures how quickly a person can read text when the print is large enough to be easily readable. A higher count represents better visual functioning.

Week 24 (n=73,72,65)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-15.756± 32.7268
GT005 High Dose [2E11 vg]-12.368± 43.2054
Untreated Control-15.769± 40.5051
Week 36 (n=71,70,65)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-18.488± 54.7913
GT005 High Dose [2E11 vg]-15.673± 31.7802
Untreated Control-3.689± 94.1057
Week 48 (n=69,67,62)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-20.734± 36.4110
GT005 High Dose [2E11 vg]-6.678± 49.0844
Untreated Control-17.297± 56.8547
Week 72 (n=57,64,53)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-24.485± 45.8525
GT005 High Dose [2E11 vg]-20.798± 39.6796
Untreated Control-26.121± 40.8016
Week 96 (n=48,47,29)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-24.678± 44.7777
GT005 High Dose [2E11 vg]-25.178± 39.7216
Untreated Control-19.242± 45.0703
Change From Baseline at Weeks 24, 36, 48, 72 and 96 in Functional Reading Independence (FRI) Index Secondary · Baseline, Weeks 24, 36, 48, 72 and 96

The FRI index is a patient-reported outcome measure developed specifically for use in GA patients. The FRI index evaluates the level of independence subjects have in performing everyday activities that require reading, such as writing a cheque or reading a prescription. Scores derived from the index range from 1 (unable to do) to 4 (total independence). A higher score represents better visual functioning.

Week 24 (n=77,75,67)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-0.4± 5.20
GT005 High Dose [2E11 vg]-1.4± 4.74
Untreated Control-0.1± 3.98
Week 36 (n=74,72,66)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-0.8± 4.64
GT005 High Dose [2E11 vg]-1.1± 4.31
Untreated Control-0.1± 4.67
Week 48 (n=70,73,65)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-0.3± 4.76
GT005 High Dose [2E11 vg]-1.4± 4.87
Untreated Control-0.2± 4.50
Week 72 (n=63,69,58)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-0.8± 4.93
GT005 High Dose [2E11 vg]-1.3± 5.19
Untreated Control-1.5± 5.37
Week 96 (n=54,51,32)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-1.4± 5.57
GT005 High Dose [2E11 vg]-1.4± 4.41
Untreated Control-1.1± 5.11
Change From Baseline at Weeks 24, 36, 48, 72 and 96 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Composite Score Secondary · Baseline, Weeks 24, 36, 48, 72 and 96

The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains. The NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the

Week 24 (n=77,78,67)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-1.466± 12.8742
GT005 High Dose [2E11 vg]-2.289± 12.3295
Untreated Control-1.270± 11.2063
Week 36 (n=74,73,66)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-1.955± 11.5060
GT005 High Dose [2E11 vg]-3.479± 12.0848
Untreated Control-2.273± 12.2395
Week 48 (n=70,74,65)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-2.501± 12.9563
GT005 High Dose [2E11 vg]-3.113± 11.9974
Untreated Control-4.403± 14.2465
Week 72 (n=63,69,54)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-4.232± 14.6259
GT005 High Dose [2E11 vg]-3.432± 11.3840
Untreated Control-6.583± 15.5133
Week 96 (n=54,51,33)
GroupValue95% CI
GT005 Medium Dose [5E10 vg]-6.341± 14.4187
GT005 High Dose [2E11 vg]-7.718± 10.9016
Untreated Control-6.804± 15.4812

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events are reported from randomization to the end of study, at Week 96, up to a maximum timeframe of approximately 96 weeks.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

GT005@Medium Dose@[5E10 vg]
Serious: 22/87 (25%)
Deaths: 4/87
GT005@High Dose@[2E11 vg]
Serious: 25/86 (29%)
Deaths: 1/86
Untreated Control
Serious: 10/82 (12%)
Deaths: 1/82
Overall
Serious: 57/255 (22%)
Deaths: 6/255

Serious adverse events (75 terms)

ReactionSystemGT005@Medium Dose@[5E10 vg]GT005@High Dose@[2E11 vg]Untreated ControlOverall
Atrial fibrillationCardiac disorders
Myocardial infarctionCardiac disorders
Retinal detachment - Study eyeEye disorders
Endophthalmitis - Study eyeInfections and infestations
SepsisInfections and infestations
Hip fractureInjury, poisoning and procedural complications
Cerebrovascular accidentNervous system disorders
SyncopeNervous system disorders
Acute kidney injuryRenal and urinary disorders
Angina pectorisCardiac disorders
Cardiac failure congestiveCardiac disorders
COVID-19Infections and infestations
PneumoniaInfections and infestations
Urinary tract infectionInfections and infestations
FallInjury, poisoning and procedural complications
Urinary retentionRenal and urinary disorders
Acute respiratory failureRespiratory, thoracic and mediastinal disorders
Acute coronary syndromeCardiac disorders
Acute myocardial infarctionCardiac disorders
Atrioventricular block completeCardiac disorders
BradycardiaCardiac disorders
Bundle branch block leftCardiac disorders
Cardiac arrestCardiac disorders
Chronic left ventricular failureCardiac disorders
Coronary artery dissectionCardiac disorders
Other adverse events (440 terms — click to expand)

ReactionSystemGT005@Medium Dose@[5E10 vg]GT005@High Dose@[2E11 vg]Untreated ControlOverall
Cataract - Study eyeEye disorders
COVID-19Infections and infestations
Retinal pigmentation - Study eyeEye disorders
Conjunctival haemorrhage - Study eyeEye disorders
Retinal haemorrhage - Study eyeEye disorders
Cataract - Fellow eyeEye disorders
Urinary tract infectionInfections and infestations
Intraocular pressure increased - Study eyeInvestigations
Eye pain - Study eyeEye disorders
Ocular hypertension - Study eyeEye disorders
Punctate keratitis - Study eyeEye disorders
Posterior capsule opacification - Fellow eyeEye disorders
Retinal tear - Study eyeEye disorders
Punctate keratitis - Fellow eyeEye disorders
Dry eye - Study eyeEye disorders
Posterior capsule opacification - Study eyeEye disorders
C-reactive protein increasedInvestigations
HypertensionVascular disorders
AnaemiaBlood and lymphatic system disorders
Anterior chamber cell - Study eyeEye disorders
Eye irritation - Study eyeEye disorders
Vitreous haemorrhage - Study eyeEye disorders
Choroidal neovascularisation - Study eyeEye disorders
Dry eye - Fellow eyeEye disorders
Vitreous floaters - Study eyeEye disorders
ArthralgiaMusculoskeletal and connective tissue disorders
Back painMusculoskeletal and connective tissue disorders
Atrial fibrillationCardiac disorders
Cataract nuclear - Study eyeEye disorders
NauseaGastrointestinal disorders
PneumoniaInfections and infestations
SinusitisInfections and infestations
Blood pressure increasedInvestigations
Lipase increasedInvestigations
HeadacheNervous system disorders
Corneal oedema - Study eyeEye disorders
Diplopia - Study eyeEye disorders
Eye pruritus - Study eyeEye disorders
Foreign body sensation in eyes - Study eyeEye disorders
Iritis - Study eyeEye disorders

Most-reported serious reactions: Atrial fibrillation, Myocardial infarction, Retinal detachment - Study eye, Endophthalmitis - Study eye, Sepsis, Hip fracture, Cerebrovascular accident, Syncope.

Data from ClinicalTrials.gov NCT04566445 adverse events section.

Sponsor's own description

The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration (AMD).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Recent Advances in Age-Related Macular Degeneration Therapies.
    Fabre M, Mateo L, Lamaa D, Baillif S, et al · · 2022 · cited 68× · PMID 36014339 · DOI 10.3390/molecules27165089
  2. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME.
    Penha FM, Masud M, Khanani ZA, Thomas M, et al · · 2024 · cited 49× · PMID 38233896 · DOI 10.1186/s40942-024-00525-9
  3. Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option.
    Qin S, Dong N, Yang M, Wang J, et al · · 2021 · cited 42× · PMID 34368372 · DOI 10.1155/2021/9945725
  4. Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration.
    Khan H, Aziz AA, Sulahria H, Khan H, et al · · 2023 · cited 40× · PMID 36741078 · DOI 10.2147/opth.s367089
  5. Interactions between Apolipoprotein E Metabolism and Retinal Inflammation in Age-Related Macular Degeneration.
    Hu ML, Quinn J, Xue K. · · 2021 · cited 39× · PMID 34210002 · DOI 10.3390/life11070635
  6. Molecular Genetic Mechanisms in Age-Related Macular Degeneration.
    Shughoury A, Sevgi DD, Ciulla TA. · · 2022 · cited 31× · PMID 35886016 · DOI 10.3390/genes13071233
  7. A Review of Completed and Ongoing Complement Inhibitor Trials for Geographic Atrophy Secondary to Age-Related Macular Degeneration.
    Halawa OA, Lin JB, Miller JW, Vavvas DG. · · 2021 · cited 31× · PMID 34208067 · DOI 10.3390/jcm10122580
  8. Complement inhibitors for age-related macular degeneration.
    Tzoumas N, Riding G, Williams MA, Steel DH. · · 2023 · cited 22× · PMID 37314061 · DOI 10.1002/14651858.cd009300.pub3

Verify or expand the search:

Other trials of GT005

Trials testing the same drug.

Other recruiting trials for Dry Age-related Macular Degeneration

Currently open trials in the same condition.

Other Gyroscope Therapeutics Limited trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04566445.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing